Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03941379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint revisedv14 Show 6 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 500 to confirmed 63
    • Primary completion date: Dec 2029 to Dec 2028
    • Eligibility criteria expanded, about 13 words
    • Site details revised at 16 of 16 sites
    • Study description shortened, about 2 words
  2. Study sites: 15 to 16v13
  3. Primary endpoint revisedv12 Show 4 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Study description shortened, about 11 words
    • Site details revised at 2 of 15 sites
    • Study title revised
  4. Site contacts updated at 3 of 15 sitesv11
  5. Site details revised at 2 of 15 sitesv10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites revised (15)v9
  2. Study sites: 9 to 15
    • Eligibility criteria revised
    • Study description expanded, about 1 word
    • Study title shortened, about 2 words
    v8
  3. Study sites: 7 to 9v7
  4. Study sites: 6 to 7v6
  5. Study sites: 5 to 6v5
  6. Re-verified, no change to tracked fieldsv4
  7. Study sites: 4 to 5v3
  8. Study sites: 2 to 4v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aura Biosciences
6 trials monitored
See 1 trial at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
The purpose of this observational research study is to follow participants who have been treated with bel-sar while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. The study will collect information based on assessments performed as part of the standard of care (SoC) for subjects with IL/CM, inclusive of all adverse events, concomitant medications and/or procedures, information regarding metastatic disease and details of treatments administered, and information about melanoma-related and all-cause mortality and cause of death (if applicable).
Trial Details
NCT Number NCT03941379
Lead Sponsor Aura Biosciences
Conditions
(from sponsor)		 Choroidal Melanoma, Indeterminate Lesions of Eye
Related terms Uveal Melanoma
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov